Last reviewed · How we verify
IMA901 and Leukine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
IMA901 and Leukine (IMA901 and Leukine) — Immatics Biotechnologies GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IMA901 and Leukine TARGET | IMA901 and Leukine | Immatics Biotechnologies GmbH | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IMA901 and Leukine CI watch — RSS
- IMA901 and Leukine CI watch — Atom
- IMA901 and Leukine CI watch — JSON
- IMA901 and Leukine alone — RSS
Cite this brief
Drug Landscape (2026). IMA901 and Leukine — Competitive Intelligence Brief. https://druglandscape.com/ci/ima901-and-leukine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing